SG11201902884YA - Fused bicylic pyridine compounds and their use as ampa receptor modulators - Google Patents

Fused bicylic pyridine compounds and their use as ampa receptor modulators

Info

Publication number
SG11201902884YA
SG11201902884YA SG11201902884YA SG11201902884YA SG11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA SG 11201902884Y A SG11201902884Y A SG 11201902884YA
Authority
SG
Singapore
Prior art keywords
san diego
california
merryfield
row
international
Prior art date
Application number
SG11201902884YA
Other languages
English (en)
Inventor
Michael K Ameriks
Márió GYURIS
Brian Ngo Laforteza
Terry Patrick Lebold
Stephen Todd Meyer
Suchitra Ravula
Brad M Savall
Brock T Shireman
Warren Stanfield Wade
János Gerencsér
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201902884YA publication Critical patent/SG11201902884YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
SG11201902884YA 2016-10-26 2017-10-20 Fused bicylic pyridine compounds and their use as ampa receptor modulators SG11201902884YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662412868P 2016-10-26 2016-10-26
PCT/US2017/057566 WO2018080917A1 (en) 2016-10-26 2017-10-20 Fused bicylic pyridine compounds and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
SG11201902884YA true SG11201902884YA (en) 2019-05-30

Family

ID=60263053

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201902884YA SG11201902884YA (en) 2016-10-26 2017-10-20 Fused bicylic pyridine compounds and their use as ampa receptor modulators

Country Status (14)

Country Link
US (1) US10087185B2 (ko)
EP (1) EP3532477B1 (ko)
JP (1) JP6953527B2 (ko)
KR (1) KR102416798B1 (ko)
CN (1) CN109963851B (ko)
AU (1) AU2017350689B2 (ko)
CA (1) CA3039676A1 (ko)
CO (1) CO2019004164A2 (ko)
EA (1) EA036903B1 (ko)
IL (1) IL266184B (ko)
MY (1) MY192333A (ko)
SG (1) SG11201902884YA (ko)
WO (1) WO2018080917A1 (ko)
ZA (1) ZA201903291B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109890823B (zh) * 2016-10-26 2021-11-30 詹森药业有限公司 稠合氮杂环化合物及其作为ampa受体调节剂的用途
AU2020231118A1 (en) * 2019-03-05 2021-10-28 Centre For Addiction And Mental Health Modulators of AMPA receptor signaling
US20220207386A1 (en) * 2020-12-28 2022-06-30 EMC IP Holding Company LLC Best outcome aiops modeling with data confidence fabrics
CN112958154B (zh) * 2021-03-07 2024-03-19 苏州大学 硅氨基稀土化合物在催化靛红化合物和环丙烯酮化合物反应中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
US20070293515A1 (en) * 2004-08-03 2007-12-20 Layton Mark E 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists
WO2008113795A1 (en) * 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP5498392B2 (ja) * 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びcns障害の治療のためのpde9aモジュレーターとしてのそれらの使用
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
GB0822425D0 (en) * 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
NZ596053A (en) * 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2011036889A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
CN109890823B (zh) * 2016-10-26 2021-11-30 詹森药业有限公司 稠合氮杂环化合物及其作为ampa受体调节剂的用途

Also Published As

Publication number Publication date
CN109963851A (zh) 2019-07-02
KR20190067239A (ko) 2019-06-14
IL266184B (en) 2021-10-31
MY192333A (en) 2022-08-17
EP3532477B1 (en) 2020-08-26
IL266184A (en) 2019-06-30
EA036903B1 (ru) 2021-01-13
NZ751998A (en) 2021-06-25
ZA201903291B (en) 2023-10-25
CO2019004164A2 (es) 2019-05-10
CA3039676A1 (en) 2018-05-03
AU2017350689B2 (en) 2021-05-20
KR102416798B1 (ko) 2022-07-04
JP2019536760A (ja) 2019-12-19
WO2018080917A1 (en) 2018-05-03
CN109963851B (zh) 2021-11-30
US10087185B2 (en) 2018-10-02
EP3532477A1 (en) 2019-09-04
JP6953527B2 (ja) 2021-10-27
US20180111933A1 (en) 2018-04-26
AU2017350689A1 (en) 2019-04-18
EA201991021A1 (ru) 2019-09-30

Similar Documents

Publication Publication Date Title
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201902884YA (en) Fused bicylic pyridine compounds and their use as ampa receptor modulators
SG11201909949XA (en) Targeted immunotolerance
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201908977SA (en) Niraparib formulations
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408501UA (en) Preparation, uses and solid forms of obeticholic acid
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201902873RA (en) Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201811559WA (en) Cancer treatment combinations
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201806401YA (en) G protein-coupled receptor (gpcr) modulation by imipridones
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof